We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Akers Bio | LSE:AKR | London | Ordinary Share | COM SHS NPV |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 57.50 | 50.00 | 65.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
25/12/2018 12:31 | Merry Xmas to any other poor soul(s) still left here. | algernon2 | |
19/12/2018 10:19 | literally. Yes indeed. here's hoping for a share price "high" then. | algernon2 | |
18/12/2018 20:28 | Looks like AKR are going to pot | buywell3 | |
18/12/2018 17:50 | "Bah Humbug" to Akers Biosciences and Raymond Akers. But a Very Merry Xmas to everyone here past present and future. | algernon2 | |
20/11/2018 12:43 | MCDid they consolidate 1 for 10?I think they must be confident of a lump out of Aker to hang in there on meagerHeparin | sambocoole | |
21/10/2018 21:33 | " Outlining the Class Action Lawsuit Against Akers Biosciences, Inc. Securities " | algernon2 | |
26/9/2018 18:43 | Ho Hum! the sound of Tumbleweed blowing through the AKR BB.Not heard anything about the impending lawsuits. Any one any news or thoughts or ideas to add to the mix? | algernon2 | |
11/8/2018 22:46 | A bounce from 21 to 28 cents on the nasdaq , may hold a different story . I am a holder for the forseable . Best of All | bbr391 | |
11/8/2018 14:35 | Friday , at around 20p a share = £2,600 worth traded = 43.33% rise 21.50 TODAY'S CHANGE 6.50 / 43.33% SHARES TRADED 12.89k | buywell3 | |
10/8/2018 21:59 | Highly suspicious past Indeed . The future holds several surprises here . That Is why I am now a long term holder , through these shenanigans . Best of All | bbr391 | |
28/7/2018 13:42 | Thanks Buywell,sent them an email yesterday but not holding my breath as they have not replied before when asked on other matters. I did get one reply once a long while ago when I enquired about visiting. | algernon2 | |
28/7/2018 11:01 | Good luck with that one | buywell3 | |
27/7/2018 10:49 | Yes this class action ongoing re investors who bought shares between certain dates should also include those who owned and held shares during those dates; as we held those shares rather than selling them , based on the same information or disinformation that the buyers may be suing Akers over. Discuss. I would (might have) have sold rather than held if I had access to accurate information and figures earlier; so I have sustained a loss here. Maybe the law firms looking at the issue could cast their nets a bit wider if they believe or can prove "evil" or "skullduggery" or "stupidity and laxness" has been at work. I shall send Akers the suggestion they respond via ADVFN BB to the comments if they have anything to say. | algernon2 | |
27/7/2018 10:40 | Today PRICE (GBX) 19.00 TODAY'S CHANGE 1.50 / 8.57% SHARES TRADED 18.58k What a larf | buywell3 | |
26/7/2018 12:19 | Akers Biosciences (AKR) News Out Just Now | danieldanj | |
18/7/2018 14:37 | Akers Biosciences (AKR) News Out Just Now | danieldanj | |
18/7/2018 11:55 | As feared, Gormally seems to have as much of a clue re PIFA Heparin / it's efficacy / selling it / etc as Walt; this is the fella who, following GNYHA having informally given the go ahead for the device to be sold in Puerto Rico, said "release the hounds". A very unusual thing for a grown man - nevermind a CEO - to say in my opinion. This is about the 15th new strategy to try to sell their 'flagship' device.... "....The Company is taking steps to improve its market presence for PIFA Heparin PF/4 Rapid Assay products including through the use of specialized Independent Sales Representatives (ISRs) and through a program to educate the marketplace through the preparation and publication of additional clinical studies" | mcmather | |
14/7/2018 09:55 | Akers Biosciences (AKR) Earnings-Reaction to Keep an Eye | danieldanj | |
13/7/2018 23:36 | Akers Biosciences (AKR) News Out Just Now | danieldanj | |
30/6/2018 18:20 | Still time to look at Akers Biosciences (AKR) - Upcoming Key Date | danieldanj | |
29/6/2018 15:02 | All you guys that ramped this POS Should say you are sorry | buywell3 | |
20/6/2018 13:00 | Is Walt getting ready for a knock at the door? "The Company is currently unable to quantify the level of recognisable revenues for the periods covered in these Reports, however it is expected that revenues will be lower than previously reported and losses for these periods will be greater". | mcmather | |
17/6/2018 18:20 | How come there is a rns (see below) on Nasdaq but not yet on here? ---------- "...The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On May 21, 2018, Akers announced that it was unable to file its Form 10-Q quarterly report with the SEC for the period ending March 31, 2018. The Company added that its internal review has expanded to include the “characterizat If you are a shareholder who suffered a loss, click here to participate....." | algernon2 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions